JB Chemicals Appoints Aman Mehta as MD, Expands Board with Three New Directors
Mumbai: J.B. Chemicals & Pharmaceuticals Limited has announced key changes to its board following shareholder approval via postal ballot, reinforcing its leadership structure and governance framework.
The company has appointed Aman Mehta as Director and Managing Director for a period of three years, effective January 21, 2026. Currently associated with Torrent Pharmaceuticals, Mehta brings significant expertise in strategic growth, mergers and acquisitions, and expansion across therapeutic segments, with a strong track record in driving both organic and inorganic growth.
Further strengthening its board, the company has appointed Amal Kelshikar, Hasmukh Patel, and Sudhir Menon as Non-Executive Non-Independent Directors with effect from March 23, 2026.
Amal Kelshikar brings over 30 years of experience in strategic planning, commercial operations, and business development, having worked with leading global pharmaceutical companies such as Abbott, Baxter, Novartis, and AstraZeneca.
Hasmukh Patel, with more than three decades of experience in the pharmaceutical industry, has played a critical role in manufacturing operations, supply chain management, and regulatory compliance, contributing to operational excellence and scalability.
Sudhir Menon, a Chartered Accountant with nearly 29 years of experience, has been instrumental in financial governance, corporate strategy, and acquisitions, currently overseeing finance, legal, and investor relations functions.
The company clarified that none of the newly appointed directors are related to each other, in line with regulatory compliance and corporate governance standards.
Also Read: JB Chemicals controlling stake to be acquired by KKR for Rs 3750 crore
